251 related articles for article (PubMed ID: 37256614)
21. Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer.
Dang C; Guo H; Najita J; Yardley D; Marcom K; Albain K; Rugo H; Miller K; Ellis M; Shapira I; Wolff AC; Carey LA; Moy B; Groarke J; Moslehi J; Krop I; Burstein HJ; Hudis C; Winer EP; Tolaney SM
JAMA Oncol; 2016 Jan; 2(1):29-36. PubMed ID: 26539793
[TBL] [Abstract][Full Text] [Related]
22. Serial Cardiovascular Magnetic Resonance Strain Measurements to Identify Cardiotoxicity in Breast Cancer: Comparison With Echocardiography.
Houbois CP; Nolan M; Somerset E; Shalmon T; Esmaeilzadeh M; Lamacie MM; Amir E; Brezden-Masley C; Koch CA; Thevakumaran Y; Yan AT; Marwick TH; Wintersperger BJ; Thavendiranathan P
JACC Cardiovasc Imaging; 2021 May; 14(5):962-974. PubMed ID: 33248962
[TBL] [Abstract][Full Text] [Related]
23. Can Quantitative CMR Tissue Characterization Adequately Identify Cardiotoxicity During Chemotherapy?: Impact of Temporal and Observer Variability.
Altaha MA; Nolan M; Marwick TH; Somerset E; Houbois C; Amir E; Yip P; Connelly KA; Michalowska M; Sussman MS; Wintersperger BJ; Thavendiranathan P
JACC Cardiovasc Imaging; 2020 Apr; 13(4):951-962. PubMed ID: 31864977
[TBL] [Abstract][Full Text] [Related]
24. Ivabradine for the Prevention of Anthracycline-Induced Cardiotoxicity in Female Patients with Primarily Breast Cancer: A Prospective, Randomized, Open-Label Clinical Trial.
Čiburienė E; Aidietienė S; Ščerbickaitė G; Sadauskienė E; Sudavičienė D; Baltruškevičienė E; Brasiūnienė B; Drobnienė M; Čelutkienė J
Medicina (Kaunas); 2023 Dec; 59(12):. PubMed ID: 38138243
[No Abstract] [Full Text] [Related]
25. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study.
Swain SM; Ewer MS; Viale G; Delaloge S; Ferrero JM; Verrill M; Colomer R; Vieira C; Werner TL; Douthwaite H; Bradley D; Waldron-Lynch M; Kiermaier A; Eng-Wong J; Dang C;
Ann Oncol; 2018 Mar; 29(3):646-653. PubMed ID: 29253081
[TBL] [Abstract][Full Text] [Related]
26. Cardiac Safety of Paclitaxel Plus Trastuzumab and Pertuzumab in Patients With HER2-Positive Metastatic Breast Cancer.
Yu AF; Manrique C; Pun S; Liu JE; Mara E; Fleisher M; Patil S; Jones LW; Steingart RM; Hudis CA; Dang CT
Oncologist; 2016 Apr; 21(4):418-24. PubMed ID: 26984450
[TBL] [Abstract][Full Text] [Related]
27. Anthracycline Therapy Is Associated With Cardiomyocyte Atrophy and Preclinical Manifestations of Heart Disease.
Ferreira de Souza T; Quinaglia A C Silva T; Osorio Costa F; Shah R; Neilan TG; Velloso L; Nadruz W; Brenelli F; Sposito AC; Matos-Souza JR; Cendes F; Coelho OR; Jerosch-Herold M; Coelho-Filho OR
JACC Cardiovasc Imaging; 2018 Aug; 11(8):1045-1055. PubMed ID: 30092965
[TBL] [Abstract][Full Text] [Related]
28. Rationale and Design of the Cardiac CARE Trial: A Randomized Trial of Troponin-Guided Neurohormonal Blockade for the Prevention of Anthracycline Cardiotoxicity.
Henriksen PA; Hall P; Oikonomidou O; MacPherson IR; Maclean M; Lewis S; McVicars H; Broom A; Scott F; McKay P; Borley A; Rowntree C; Lord S; Collins G; Radford J; Guppy A; Payne JR; Newby DE; Mills NL; Lang NN
Circ Heart Fail; 2022 Jul; 15(7):e009445. PubMed ID: 35766037
[TBL] [Abstract][Full Text] [Related]
29. Usefulness of Integrating Heart Failure Risk Factors Into Impairment of Global Longitudinal Strain to Predict Anthracycline-Related Cardiac Dysfunction.
Milks MW; Velez MR; Mehta N; Ishola A; Van Houten T; Yildiz VO; Reinbolt R; Lustberg M; Smith SA; Orsinelli DA
Am J Cardiol; 2018 Apr; 121(7):867-873. PubMed ID: 29454478
[TBL] [Abstract][Full Text] [Related]
30. Dynamic Changes in High-Sensitivity Cardiac Troponin I in Response to Anthracycline-Based Chemotherapy.
Tzolos E; Adamson PD; Hall PS; Macpherson IR; Oikonomidou O; MacLean M; Lewis SC; McVicars H; Newby DE; Mills NL; Lang NN; Henriksen PA
Clin Oncol (R Coll Radiol); 2020 May; 32(5):292-297. PubMed ID: 31813662
[TBL] [Abstract][Full Text] [Related]
31. Strain-Guided Management of Potentially Cardiotoxic Cancer Therapy.
Thavendiranathan P; Negishi T; Somerset E; Negishi K; Penicka M; Lemieux J; Aakhus S; Miyazaki S; Shirazi M; Galderisi M; Marwick TH;
J Am Coll Cardiol; 2021 Feb; 77(4):392-401. PubMed ID: 33220426
[TBL] [Abstract][Full Text] [Related]
32. Paraoxonase-1 Activity in Breast Cancer Patients Treated With Doxorubicin With or Without Trastuzumab.
Thompson EW; Demissei BG; Smith AM; Brahmbhatt P; Wang J; Clark A; DeMichele A; Narayan V; Shah P; Sun L; Lefebvre B; Fradley MG; Carver JR; Tang WHW; Ky B
JACC Basic Transl Sci; 2022 Jan; 7(1):1-10. PubMed ID: 35128203
[TBL] [Abstract][Full Text] [Related]
33. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
Yu AF; Singh JC; Wang R; Liu JE; Eaton A; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
Oncologist; 2017 Jun; 22(6):642-647. PubMed ID: 28341761
[TBL] [Abstract][Full Text] [Related]
34. Rationale and Design of the Strain Surveillance of Chemotherapy for Improving Cardiovascular Outcomes: The SUCCOUR Trial.
Negishi T; Thavendiranathan P; Negishi K; Marwick TH;
JACC Cardiovasc Imaging; 2018 Aug; 11(8):1098-1105. PubMed ID: 29909105
[TBL] [Abstract][Full Text] [Related]
35. Activation recovery interval as an electrocardiographic repolarization index to detect doxorubicin-induced cardiotoxicity.
Kinoshita T; Onda N; Ohno R; Ikeda T; Sugizaki Y; Ohara H; Nakagami T; Yuzawa H; Shimada H; Shimizu K; Ikeda T
J Cardiol; 2023 Dec; 82(6):473-480. PubMed ID: 37506822
[TBL] [Abstract][Full Text] [Related]
36. A randomized trial to evaluate the impact of exercise-based cardiac rehabilitation for the prevention of chemotherapy-induced cardiotoxicity in patients with breast cancer: ONCORE study protocol.
Díaz-Balboa E; González-Salvado V; Rodríguez-Romero B; Martínez-Monzonís A; Pedreira-Pérez M; Palacios-Ozores P; López-López R; Peña-Gil C; González-Juanatey JR
BMC Cardiovasc Disord; 2021 Apr; 21(1):165. PubMed ID: 33827450
[TBL] [Abstract][Full Text] [Related]
37. Early diagnostic value of high-sensitivity cardiac troponin T for cancer treatment-related cardiac dysfunction: a meta-analysis.
Lv X; Pan C; Guo H; Chang J; Gao X; Wu X; Zhi X; Ren C; Chen Q; Jiang H; Zhao X; Liu K; Li Y
ESC Heart Fail; 2023 Aug; 10(4):2170-2182. PubMed ID: 37170474
[TBL] [Abstract][Full Text] [Related]
38. Baseline Troponin Level and Cardiac Toxicity in HER2-positive Early Breast Cancer Patients Receiving Trastuzumab.
Canale ML; Casolo G; Donati S; Bisceglia I; Puccetti C; Amoroso D; Venturini E; Maurea N; Turazza FM; Camerini A
In Vivo; 2023; 37(5):2139-2146. PubMed ID: 37652487
[TBL] [Abstract][Full Text] [Related]
39. Nomogram for Predicting Risk of Cancer Therapy-Related Cardiac Dysfunction in Patients With Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.
Yu AF; Lin IH; Jorgensen J; Copeland-Halperin R; Feldman S; Ibtida I; Assefa A; Johnson MN; Dang CT; Liu JE; Steingart RM
J Am Heart Assoc; 2023 Oct; 12(19):e029465. PubMed ID: 37750581
[TBL] [Abstract][Full Text] [Related]
40. Association between insulin resistance and cardiac remodeling in HER2-positive breast cancer patients: a real-world study.
Shi Y; Qiu Z; Yu J; Li Z; Hua S; Chen Y; Chen X; Shen K; Jin W
BMC Cancer; 2023 Jul; 23(1):615. PubMed ID: 37400804
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
